ProQR Therapeutics NV(PRQR) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

Current Price

$6.19

RSI

42.553

Beta:

0.539437

July 14, 2020
5.6M

-7.571 %
-32.458 %

$0
$0
$0
$0
$0
$0
%
%
%
0.000 %
0.000 %

$-56,614,000
$-37,085,000
$-43,673,000
$-39,103,000
$-20,832,000
$-12,127,000
-34.495 %
17.765 %
-10.464 %
-46.725 %
-41.787 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.